Genpharmasec

Who are the top shareholders of the Genpharmasec?

The top shareholders of Genpharmasec are Sneha Sadhwani, the promoter with 16.8%, and public shareholder Yogeshkumar Rasiklal Sanghavi with 7.07%. Individual investors hold a combined 59.94% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Genpharmasec include Sneha Sadhwani, who is the promoter with the highest holding at 16.8%. The highest public shareholder is Yogeshkumar Rasiklal Sanghavi, holding 7.07%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 59.94% of the shares. There are no institutional holdings or pledged promoter holdings reported.

When is the next results date for Genpharmasec?

No Upcoming Board Meetings

Who are in the management team of Genpharmasec?

As of March 2022, the management team of Genpharmasec includes Ulhas Narayan Deosthale (Executive Director), Rajesh Sadhwani and Sneha Sadhwani (Non-Executive Directors), Siddhesh Shankar Shende, Mayur Bharatbhai Bhatt, and Sachin Aphandkar (Independent Directors), along with Heta Shah (Company Secretary & Compliance Officer).

As of March 2022, the management team of Genpharmasec includes the following individuals:<BR><BR>1. Ulhas Narayan Deosthale - Executive Director / Whole Time<BR>2. Rajesh Sadhwani - Non-Executive & Non-Independent Director<BR>3. Sneha Sadhwani - Non-Executive & Non-Independent Director<BR>4. Siddhesh Shankar Shende - Independent Non-Executive Director<BR>5. Mayur Bharatbhai Bhatt - Independent Director<BR>6. Sachin Aphandkar - Independent Director<BR>7. Heta Shah - Company Secretary & Compliance Officer<BR><BR>These members play various roles within the company's governance structure.

What does Genpharmasec do?

Genpharmasec Ltd, a Micro Cap company in the Trading & Distributors industry, was incorporated in 1992 and reported net sales of 14 Cr and a net profit of 0 Cr for the quarter ending March 2025. The company has a market cap of Rs 116 Cr and key metrics include a P/E of 46.00 and a return on equity of 3.76%.

Overview:<BR>Genpharmasec Ltd operates in the Trading & Distributors industry and is classified as a Micro Cap company.<BR><BR>History:<BR>Genpharmasec Ltd was originally incorporated as a Public Limited Company on November 16, 1992, in the State of Gujarat under the name "Adi Rasayan Limited." The company changed its name to "Genpharmasec Limited" on November 27, 2018. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 14 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 116 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 46.00 <BR>Industry P/E: 30 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 3.76% <BR>Price to Book: 1.75 <BR><BR>Contact Details:<BR>Address: Office 104 & 105 1st Flr, Gundecha Indl Kandivali (East) Mumbai Maharashtra : 400101 <BR>Email: genericpharmasec09@gmail.com <BR>Website: http://www.genpharmasec.com

Has Genpharmasec declared dividend?

No Dividend History Available

Who are the peers of the Genpharmasec?

Genpharmasec's peers include Redington, MMTC, MSTC, Ravindra Energy, Cravatex, Dhanlaxmi Cotex, Excel Realty, and Safa Systems. Redington shows excellent management and growth, while Dhanlaxmi Cotex has the highest 1-year return at 220.06%, and Genpharmasec's return is 2.42%.

Peers: The peers of Genpharmasec are Redington, MMTC, MSTC, Ravindra Energy, Cravatex, Dhanlaxmi Cotex, Excel Realty, and Safa Systems.<BR><BR>Quality Snapshot: Excellent management risk is observed at Redington, while Average management risk is found at MMTC, MSTC, and Cravatex, and the rest have Below Average management risk. Growth is Excellent at Redington, while Average growth is noted at Dhanlaxmi Cotex, and Below Average growth is found at MMTC, MSTC, Ravindra Energy, Cravatex, Excel Realty, Safa Systems, and the rest. For Capital Structure, Excellent ratings are seen at MSTC and Dhanlaxmi Cotex, Good at Genpharmasec, and Below Average at MMTC, Ravindra Energy, Cravatex, Excel Realty, and Safa Systems.<BR><BR>Return Snapshot: Dhanlaxmi Cotex has the highest 1-year return at 220.06%, while MSTC has the lowest at -39.89%. Genpharmasec's 1-year return of 2.42% is significantly lower than Dhanlaxmi Cotex's return but higher than MSTC's. Additionally, the six-month return is negative for MSTC, Genpharmasec, and Excel Realty.

Should I buy, sell or hold Genpharmasec?

What is the technical trend for Genpharmasec?

As of May 13, 2025, Genpharmasec's technical trend is mildly bearish, influenced by bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

As of 13 May 2025, the technical trend for Genpharmasec has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, and Bollinger Bands show a bearish trend on both weekly and monthly time frames. The KST is mildly bullish weekly but bearish monthly, and Dow Theory indicates a mildly bullish trend on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands, despite some mildly bullish signals in the weekly MACD and KST.

How big is Genpharmasec?

As of 24th July, Genpharmasec Ltd has a market capitalization of 112.00 Cr, with Net Sales of 33.72 Cr and a Net Profit of 1.54 Cr reported in the latest four quarters. Shareholder's Funds are 64.40 Cr and Total Assets amount to 70.70 Cr as of March 2024.

As of 24th July, Genpharmasec Ltd has a market capitalization of 112.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, Genpharmasec reported Net Sales of 33.72 Cr and a Net Profit of 1.54 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 64.40 Cr and Total Assets of 70.70 Cr.

Are Genpharmasec latest results good or bad?

Genpharmasec's latest results are very positive, with a Profit After Tax of Rs 1.22 crore, a 216.9% increase from the previous four quarters, and net sales rising to Rs 12.04 crore, up 42.8%. Overall, the company shows strong growth and improved financial health.

Genpharmasec's latest results can be considered very positive. For the quarter ending June 2025, the company reported a Profit After Tax (PAT) of Rs 1.22 crore, which is a remarkable growth of 216.9% compared to the average PAT of Rs 0.39 crore over the previous four quarters. This is the highest PAT the company has achieved in the last five quarters, indicating a strong upward trend in profitability.<BR><BR>Net sales also showed significant improvement, reaching Rs 12.04 crore, marking a 42.8% increase from the average of Rs 8.43 crore in the prior four quarters. The operating profit (PBDIT) and Profit Before Tax (PBT) also reached their highest levels in five quarters, further highlighting the company's strong performance.<BR><BR>Additionally, the Earnings per Share (EPS) of Rs 0.02 reflects the company's enhanced profitability and commitment to delivering value to shareholders. Overall, these results suggest that Genpharmasec is on a positive trajectory, showcasing strong growth and improved financial health.

Is Genpharmasec overvalued or undervalued?

As of August 8, 2025, Genpharmasec is considered overvalued with a PE ratio of 45.35 and negative ROCE, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -35.60%.

As of 8 August 2025, Genpharmasec's valuation grade has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently considered overvalued, with a PE ratio of 45.35, an EV to EBITDA ratio of 111.26, and a PEG ratio of 0.10. These ratios suggest that the stock is trading at a premium compared to its earnings potential, especially when considering its negative ROCE of -0.42% and a low ROE of 1.25%.<BR><BR>In comparison to its peers, Genpharmasec's valuation stands out as particularly high. For instance, Lloyds Enterprises has a PE ratio of 186.85 and MMTC has a PE ratio of 133.83, both categorized as risky, while PTC India, which is very attractive, has a PE ratio of just 8.33. This stark contrast highlights the overvaluation of Genpharmasec within its industry. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -35.60% compared to the Sensex's 2.20%, further reinforcing the notion that Genpharmasec is overvalued.

How has been the historical performance of Genpharmasec?

Genpharmasec has experienced steady revenue growth from 25.52 Cr in Mar'23 to 33.72 Cr in Mar'25, but operating profit has fluctuated, with a recovery in profit after tax from a loss in Mar'24 to 1.23 Cr in Mar'25. The company faces challenges in managing expenses and cash flow despite overall growth.

Answer:<BR>The historical performance of Genpharmasec shows a mixed trend over the past three years, with notable fluctuations in revenue and profit metrics.<BR><BR>Breakdown:<BR>Genpharmasec's net sales have increased from 25.52 Cr in Mar'23 to 30.41 Cr in Mar'24, and further to 33.72 Cr in Mar'25, indicating a steady growth in total operating income. The total expenditure has also risen, from 25.26 Cr in Mar'23 to 30.36 Cr in Mar'24, and 33.66 Cr in Mar'25, reflecting increased costs in purchases and employee expenses. Operating profit, however, has shown variability, with a peak of 0.36 Cr in Mar'23, dropping to 0.05 Cr in Mar'24, and slightly recovering to 0.06 Cr in Mar'25. Profit before tax improved significantly from 0.28 Cr in Mar'23 to 1.88 Cr in Mar'25, while profit after tax showed a recovery from a loss of 0.17 Cr in Mar'24 to a profit of 1.23 Cr in Mar'25. The company's total assets have increased from 19.03 Cr in Mar'23 to 79.43 Cr in Mar'25, with total liabilities also rising from 19.03 Cr to 79.43 Cr in the same period. Cash flow from operating activities improved from -3.00 Cr in Mar'23 to 2.00 Cr in Mar'25, although the net cash outflow was -13.00 Cr in Mar'25, down from a net inflow of 16.00 Cr in Mar'24. Overall, while Genpharmasec has shown growth in sales and profit recovery, it faces challenges in managing expenses and cash flow.

Which are the latest news on Genpharmasec?

Why is Genpharmasec Ltd falling/rising?

As of 03-Feb, Genpharmasec Ltd's stock price has risen by 2.63% after two days of decline, but it remains below key moving averages and has experienced significant long-term losses of over 53% in the past year. The company's weak fundamentals and declining investor participation suggest ongoing challenges despite the recent uptick.

As of 03-Feb, Genpharmasec Ltd's stock price is rising, having increased by 0.03, or 2.63%. This rise follows a trend reversal after two consecutive days of decline. Despite this uptick, the stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating that it has not yet regained a strong upward momentum.<BR><BR>The overall performance of the stock has been poor in the longer term, with a significant decline of 53.20% over the past year and 80.99% over the past five years. This long-term underperformance is compounded by weak operating profits and a negative EBIT to Interest ratio of -0.64, which suggests challenges in servicing debt. Additionally, there has been a decrease in investor participation, as evidenced by a 14.83% drop in delivery volume compared to the 5-day average.<BR><BR>While there were positive results reported on September 25, including the highest operating cash flow and net sales, the company's weak long-term fundamental strength and negative operating profits contribute to a perception of risk among investors. Thus, while the stock is experiencing a short-term rise, the broader context of its performance and fundamentals indicates ongoing challenges.